By Ciobanu Sebastian — Founder & Head of Product, Folliq · Published 27 September 2026
Key Takeaways
- The best-known trial found topical caffeine performed close to 5% minoxidil after six months — but it was funded by the caffeine shampoo's own manufacturer, and neither researchers nor participants were blinded to which product they used.
- A 2025 systematic review of nine studies found the evidence "in favour" across the board, but rated the underlying study quality as low or very low in six of the nine.
- Caffeine needs real contact time on the scalp to plausibly do anything — around two minutes, not the quick rinse most people give a shampoo.
- Folliq doesn't sell a caffeine product. This article exists because it's a topical active people ask us about, not to lead you toward one of ours.
Caffeine shows up in an unusual number of hair products, from serums to a well-known German shampoo brand's entire product line. The pitch is appealingly simple: it's cheap, it's already in your kitchen, and there's a real trial behind it. What that trial actually says, and how strong the rest of the evidence is, deserves a closer look than most product pages give it.
What caffeine is proposed to do
The mechanism isn't exotic pharmacology. Caffeine is a methylxanthine that inhibits phosphodiesterase enzymes, which raises intracellular cAMP levels in cells it reaches. Higher cAMP is associated with increased cell metabolism and proliferation — in this case, theoretically, in the cells of the hair follicle and dermal papilla. Separately, some researchers have proposed that caffeine may counteract testosterone-driven suppression of hair follicle growth at the cellular level, though this part of the mechanism is less thoroughly established than the cAMP pathway.
None of that requires caffeine to be ingested — the proposed action is local, on cells the caffeine physically reaches, which is why it's formulated as a topical rather than sold as a supplement.
The trial everyone cites, read carefully
The study behind most caffeine-shampoo marketing is a 2017 open-label, randomized, multicenter trial comparing a 0.2% caffeine-based topical liquid against 5% minoxidil solution in 210 men with androgenetic alopecia, followed for six months.¹ At the six-month mark, the minoxidil group showed an 11.68% mean improvement in anagen hair ratio, against 10.59% for the caffeine group — a gap of 1.09 percentage points, with a confidence interval that stayed inside the trial's predefined non-inferiority margin. On that basis, the authors concluded caffeine was not inferior to minoxidil on this measure.
Two things about this trial are worth knowing before you weight it heavily. First, it was open-label — both the researchers assessing hair and the men using the products knew which one they had, which is a real source of bias in a measure that involves some degree of visual judgment. Second, and more directly relevant: the trial was funded by Dr. Kurt Wolff GmbH & Co. KG, the manufacturer of the caffeine liquid being tested, and two of the study's authors were an employee and a paid consultant of that company. That doesn't make the result false, but it's not an independent trial, and treating it as one overstates what it actually is.
The newer study, and what it doesn't test
A more recent 2024 study looked at a daily shampoo combining 0.4% caffeine with 0.2% adenosine in 77 people over the study period, and found hair density rose from 118.25 to 130.03 hairs/cm², with reported shedding episodes dropping from 27.19 to 17.53.² Those are meaningful-sounding numbers, and worth two caveats. It tested caffeine combined with adenosine, not caffeine alone, so it can't tell you what caffeine on its own contributed. And hair shaft diameter — a separate, thickness-related measure — did not change significantly in the same study, even as density and shedding did.
What the wider evidence base actually looks like
A 2025 systematic review pulled together nine studies on topical caffeine for hair loss — five randomized controlled trials, three prospective cohort studies, and one twin-pair study — covering androgenetic alopecia, telogen effluvium, and alopecia areata.³ Every one of the nine studies reported a result in caffeine's favour. That sounds like consensus, until you read how the reviewers rated the underlying evidence quality: medium in three of the nine studies, low in one, and very low in the remaining five. The review also noted that none of the studies used tattooed or otherwise marked scalp sites to standardise where hair counts were taken between visits — a basic methodological safeguard against measurement drift that the field hasn't consistently adopted.
Put plainly: nine studies agreeing sounds more convincing than it is when six of those nine are rated low-to-very-low quality by the people who reviewed them. The honest read is "consistently reported as helpful, not yet proven at a rigour that should end the conversation" — which is a genuinely different claim than "clinically proven," and the distinction matters.
If you're going to try it: contact time is the variable that matters
Whatever effect caffeine has requires it to actually reach the follicle in a usable concentration, and that takes longer than a normal shower allows. The contact times used in trials with reported effects run around two minutes on the scalp — most people give a shampoo something closer to thirty seconds before rinsing. If you're testing a caffeine shampoo against its own trial evidence, the trial's contact time is part of what you'd need to match, not an optional detail.
This is also, incidentally, one honest reason a longer scalp massage routine — the kind covered in our scalp care routine guide — plausibly helps any topical do more than a quick rinse-and-go application, independent of which active is in the bottle.
Caffeine versus rosemary oil, briefly
Both ingredients get compared to minoxidil in their respective trials, and both comparisons deserve the same scepticism for similar reasons — small or industry-linked studies, non-inferiority framing rather than head-to-head superiority. We've covered rosemary's evidence base, including where it thins out, in our article on the rosemary oil trial. Neither ingredient has a trial demonstrating it beats minoxidil outright; both have trials suggesting they may not be far behind it, from researchers with a stake in the answer.
What we're not going to tell you
Folliq doesn't formulate or sell a caffeine product, so there's no version of this article that ends in a product recommendation from us — which is, if anything, a reason to trust the caveats above rather than read past them. If you're already using a caffeine shampoo or serum and it's not irritating your scalp, the evidence doesn't give you a strong reason to stop. It also doesn't give you a strong reason to expect it to outperform better-studied options, or to skip a dermatologist visit if your shedding is significant.
When to see a dermatologist
See a dermatologist rather than relying on a caffeine product alone if your hair loss is sudden, patchy, or accompanied by scalp pain, scaling, or scarring; if you've used a caffeine shampoo consistently for six months without any change; or if you're trying to decide between caffeine and a prescription option like minoxidil or finasteride and want guidance based on your specific pattern of loss rather than a product's marketing claims.
Nothing in this article is medical advice and it cannot assess your situation. Folliq products are cosmetic products, not medical devices, and are not intended to diagnose, treat, cure or prevent any disease.
References
- Dhurat R, Chitallia J, May TW, et al. An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia. Skin Pharmacol Physiol. 2017;30(6):298–305. PMID 29055953.
- Chen J, et al. Anti-hair loss effect of a shampoo containing caffeine and adenosine. J Cosmet Dermatol. 2024;23(9):2927–2933. PMID 38764299.
- Systematic review of nine studies on topical caffeine for non-scarring alopecia. J Drugs Dermatol. 2025. PMID 39997270.